+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer



Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer



Ajr. American Journal of Roentgenology 183(2): 519-524



Our goal was to evaluate the impact of image fusion on the interpretation of indium-111 Prosta-Scint SPECT scans. Sixty-seven consecutive patients referred for rising prostate-specific antigen (PSA) levels after initial therapy for primary prostate cancer underwent SPECT 96 hr after infusion of (111)In Prosta-Scint, with simultaneous technetium-99m blood pool imaging. Volume data sets from the SPECT scans were then fused with those from CT and MR images of the pelvis using a 3D landmark-based warping program. The SPECT scans were initially interpreted without benefit of MRI or CT fusion. The fused Prosta-Scint MRI-CT volumes were reevaluated by a nuclear radiologist and an MRI radiologist. Independent reviews before and after fusion were available in these patients. Validation of results after fusion was performed through correlation with PSA changes after radiation therapy. Six patients with sites that could not be evaluated and three without their original Prosta-Scint scanning reports were excluded; thus, 58 patients were studied clinically. Seventy-four of 161 prefusion-positive sites were found to be negative after fusion. These 74 sites subsequently were identified primarily as showing bowel, vessel, or marrow uptake after fusion. In two patients, nodal disease was identified although the review before perfusion indicated none. Twenty-five patients previously thought to have nodal disease appeared to have only local disease after fusion. After local radiation therapy, PSA levels decreased in 12 of 25 patients, increased in five, and were unavailable in eight. Although Prosta-Scint SPECT alone can help in the proper management of recurrent prostate cancer, fusion with MRI-CT of the pelvis can improve the specificity of the examination.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049296574

Download citation: RISBibTeXText

PMID: 15269050

DOI: 10.2214/ajr.183.2.1830519


Related references

Impact of image fusion of 111In Capromab Pendetide with MR or CT in patients with recurrent prostate CA. Journal of Nuclear Medicine 42(5 Suppl.): 294P, 2001

Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Review of Anticancer Therapy 8(2): 175-181, 2008

Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clinical Nuclear Medicine 23(10): 672-677, 1998

Contemporary Use Of Ct-Fused Indium-111 Capromab Pendetide Immunoscintigraphy In The Management Of Recurrent Prostate Cancer. The Journal of Urology 183(4): e337-e338, 2010

Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer. Urology 54(6): 1058-1063, 1999

Indium-111 Capromab pendetide fails to reliably detect metastases in patients before and after treatment for localized prostate cancer. Journal of Nuclear Medicine 39(5 Suppl. ): 150P, 1998

Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer. Urology 70(2): 303-308, 2007

Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 94(4): 987-996, 2002

Prostate cancer abdominal metastases detected with indium-111 capromab pendetide. Journal of Nuclear Medicine 39(4): 650-652, 1998

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. Journal of Urology 159(6): 2041-2047, 1998

Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 83(4): 739-747,. 15, 1998

Radioimmunoguided surgery using indium-111 capromab pendetide (PROSTASCINT) to diagnose supraclavicular metastasis from prostate cancer. Urology 56(4): 669, 2000

111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. Journal of Urology 159(6): 2041-6; Discussion 2046-7, 1998

Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging. International Journal of Radiation Oncology Biology Physics 81(4): E423-E429, 2011

A Prospective Trial of Intensity Modulated Radiation Therapy Incorporating a 111-Indium-Capromab Pendetide Guided Boost for Prostate Cancer: Ten-Year Outcomes. International Journal of Radiation Oncology*biology*physics 96(2): E235-E236, 2016